序号 |
标题 |
次数 |
作者 |
发布时间 |
75736 |
MAL-di-EG-Val-Cit-PAB-MMAF, ADC试剂 |
85 |
kx |
2024-12-19 |
75737 |
cas:2353409-45-5 endo BCN-PEG3-VC-PFP Ester |
98 |
zyl |
2024-12-19 |
75738 |
Hydrazone-doxorubicin, ADC试剂 |
169 |
kx |
2024-12-19 |
75739 |
DBCO-C4-Val-Cit-PABC-PNP |
77 |
zyl |
2024-12-19 |
75740 |
cas:644981-35-1 Val-Cit-PAB-MMAE |
84 |
zyl |
2024-12-19 |
75741 |
cas:170908-81-3,DOTA-NHS ester ,1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸 1-(2,5-二氧代-1-吡咯烷基)酯 |
73 |
kx |
2024-12-19 |
75742 |
endo-BCN-PEG4-Val-Cit-PAB-MMAE的介绍 |
82 |
zyl |
2024-12-19 |
75743 |
cas:2259318-50-6,MA-PEG4-VA-PBD , ADC试剂 |
97 |
kx |
2024-12-19 |
75744 |
CAS: 2259318-55-1 - DBCO-(PEG2-VC-PAB-MMAE)2 |
65 |
WYQ |
2024-12-19 |
75745 |
CAS: 2768446-73-5,DBCO-Val-Cit-PAB-MMAE |
79 |
WYQ |
2024-12-19 |
75746 |
MC-vc-PAB-C6-a-amanitin, ADC试剂 |
70 |
kx |
2024-12-19 |
75747 |
cas:663598-98-9,2,5-dioxopyrrolidin-1-yl 4-methyl-4-((5-nitropyridin-2-yl)disulfanyl)pentanoate,ADC定制 |
90 |
wyh |
2024-12-19 |
75748 |
cas:2873452-49-2 MC-EVCit-PAB-MMAE |
87 |
zyl |
2024-12-19 |
75749 |
2,5-dioxopyrrolidin-1-yl 3-methyl-3-(pyridin-2-yldisulfanyl)butanoate,ADC定制 |
95 |
wyh |
2024-12-19 |
75750 |
cas:159857-70-2 MC-Val-Cit-Doxorubicin |
118 |
zyl |
2024-12-19 |
75751 |
Gly3-vc-PAB-MMAE, ADC试剂 |
103 |
kx |
2024-12-19 |
75752 |
CAS: 1869126-64-6, Azido-PEG4-Val-Cit-PAB-MMAE |
87 |
WYQ |
2024-12-19 |
75753 |
cas:2353409-54-6 , Mal-amido-PEG8-Val-Gly,ADC定制 |
104 |
wyh |
2024-12-19 |
75754 |
Azido-PEG4-Val-Ala-PAB-PNP |
99 |
zyl |
2024-12-19 |
75755 |
NOTA-(NGR)2 NOTA偶联NGR二聚体 |
78 |
h |
2024-12-19 |
75756 |
1-(2,5-dioxopyrrolidin-1-yloxy)-4-((5-nitropyridin-2-yl)disulfanyl)-1-oxobutane-2-sulfonic acid,ADC定制 |
89 |
wyh |
2024-12-19 |
75757 |
CAS: 1343476-44-7,Val-Ala-PAB-OH |
79 |
WYQ |
2024-12-19 |
75758 |
MC-PBD, ADC试剂 |
88 |
kx |
2024-12-19 |
75759 |
Mal-Val-Ala-PAB的介绍 |
90 |
zyl |
2024-12-19 |
75760 |
DOTA-K-A9 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)结合肽A9 |
79 |
h |
2024-12-19 |
75761 |
Azide-PEG3-Val-Cit-PAB-MMAF,叠氮-三聚乙二醇-Val-Cit-PAB-MMAF |
83 |
WYQ |
2024-12-19 |
75762 |
Arm-DOTA-B72.3 |
77 |
h |
2024-12-19 |
75763 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
93 |
zyl |
2024-12-19 |
75764 |
(Lys(DOTA)4)BVD15 DOTA偶联神经肽Y(NPY)类似物 |
126 |
h |
2024-12-19 |
75765 |
1801838-28-7,Mc-vc-PAB-SN38,化合物MC-VC-PAB-SN38 |
87 |
kx |
2024-12-19 |
75766 |
DOTA-PPI 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)-官能化的聚(丙烯亚胺)(PPI)糖树枝状分子 |
89 |
h |
2024-12-19 |
75767 |
CAS: 863971-17-9,MC-Val-Cit-PAB-MMAF |
110 |
WYQ |
2024-12-19 |
75768 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
124 |
zyl |
2024-12-19 |
75769 |
DBCO-PEG4-vc-PAB-MMAE, ADC试剂 |
112 |
kx |
2024-12-19 |
75770 |
1884578-00-0,Boc-PEG4-Val-Ala-PAB-PNP,ADC定制 |
114 |
wyh |
2024-12-19 |
75771 |
DOTA-Peg-Cpa-c[DCys-Aph(Cbm)-DTrp-Lys-Thr-Cys]-2Nal-NH2 |
77 |
h |
2024-12-19 |
75772 |
DOTA-2.5D DOTA-胱氨酸结肽(knottins)2.5D和2.5F |
94 |
h |
2024-12-19 |
75773 |
二苯并环辛炔-四聚乙二醇-VAL-ALA-PAB,ADC定制 |
114 |
wyh |
2024-12-19 |
75774 |
Hz220(DOTA-Lys(IR dye 650)-PEa(4)-[D-Phe(6)DOTA偶联的GRPr拮抗剂 |
91 |
h |
2024-12-19 |
75775 |
Azido-PEG4-MMAE,抗体药物偶联物(ADCs) |
123 |
WYQ |
2024-12-19 |
75776 |
1626359-62-3,SPDB-DM4, ADC试剂 |
81 |
kx |
2024-12-19 |
75777 |
Acid-PEG4-Val-Cit-PAB-MMAE,包含PEG链和MMAE等部分 |
87 |
WYQ |
2024-12-19 |
75778 |
cas:159857-70-2,MC-Val-Cit-Doxorubicin,ADC定制 |
110 |
wyh |
2024-12-19 |
75779 |
DOTA-(D)Phe(1)-Tyr(3) |
82 |
h |
2024-12-19 |
75780 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
123 |
zyl |
2024-12-19 |